In our study, three different BCR/ABL dependent mechanisms of imatinib resistance; ABL kinase domain mutations, mutations in SH3-SH2 domain of BCR/ABL gene and BCR/ABL amplification were studied in CML patients exhibiting clinical resistance to imatinib. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.